Abbisko Cayman
Abbisko Cayman, a leading biopharmaceutical company headquartered in the Cayman Islands (CN), is at the forefront of innovative drug discovery and development. Founded in 2016, Abbisko has rapidly established itself in the oncology sector, focusing on small molecule therapeutics that target cancer pathways. With a strong presence in both the Asian and global markets, Abbisko Cayman is renowned for its unique approach to drug design, leveraging advanced technologies to create highly selective compounds. The company’s core products include a range of investigational drugs that aim to address unmet medical needs in cancer treatment. Abbisko's commitment to excellence has positioned it as a notable player in the biopharmaceutical industry, with significant achievements in clinical trials and partnerships that enhance its research capabilities.
DitchCarbon Score
How does Abbisko Cayman's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abbisko Cayman's score of 10 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Abbisko Cayman's reported carbon emissions
In 2023, Abbisko Cayman reported total carbon emissions of approximately 1,453,330 kg CO2e, comprising 9,100 kg CO2e from Scope 1 and 1,443,230 kg CO2e from Scope 2 emissions. The company has shown an increase in emissions compared to 2022, where total emissions were about 1,020,000 kg CO2e, with Scope 1 emissions at 13,350 kg CO2e and Scope 2 emissions at 1,009,650 kg CO2e. In 2021, Abbisko Cayman recorded total emissions of around 821,310 kg CO2e, with Scope 1 emissions at 5,910 kg CO2e and Scope 2 emissions at 815,400 kg CO2e. This indicates a trend of increasing emissions over the past three years. Despite the rising emissions, Abbisko Cayman has not disclosed any specific reduction targets or initiatives as part of their climate commitments. The absence of a climate pledge or science-based targets suggests that the company may need to enhance its sustainability strategies to align with industry standards for carbon reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 5,910 | 00,000 | 0,000 |
| Scope 2 | 815,400 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Abbisko Cayman is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
